Show simple item record

dc.creatorZarić, Božidarka
dc.creatorObradović, Milan M.
dc.creatorSudar-Milovanović, Emina
dc.creatorNedeljković, Jovan
dc.creatorLazić, Vesna M.
dc.creatorIsenović, Esma R.
dc.date.accessioned2019-12-04T13:46:32Z
dc.date.available2019-12-04T13:46:32Z
dc.date.issued2019
dc.identifier.issn1381-6128
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/8378
dc.description.abstractBackground: Insulin is essential for the treatment of Type 1 diabetes mellitus (T1DM) and is necessary in numerous cases of Type 2 diabetes mellitus (T2DM). Prolonged administration of anti-diabetic therapy is necessary for the maintenance of the normal glucose levels and thereby preventing vascular complications. A better understanding of the disease per se and the technological progress contribute to the development of new approaches with the aim to achieve better glycemic control. Objective: Current therapies for DM are faced with some challenges. The purpose of this review is to analyze in detail the current trends for insulin delivery systems for diabetes treatment. Results: Contemporary ways have been proposed for the management of both types of diabetes by adequate application of drug via subcutaneous, buccal, oral, ocular, nasal, rectal and pulmonary ways. Development of improved oral administration of insulin is beneficial regarding mimicking physiological pathway of insulin and minimizing the discomfort of the patient. Various nanoparticle carriers for oral and other ways of insulin delivery are currently being developed. Engineered specific properties of nanoparticles (NP): controlling toxicity of NP, stability and drug release, can allow delivery of higher concentration of the drug to the desired location. Conclusions: The successful development of any drug delivery system relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission. © 2019 Bentham Science Publishers.en
dc.language.isoen
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173033/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173034/RS//
dc.rightsrestrictedAccess
dc.sourceCurrent Pharmaceutical Design
dc.subjectDiabetes type 1en
dc.subjectDiabetes type 2en
dc.subjectdelivery systemsen
dc.subjectinsulinen
dc.subjectnanoparticlesen
dc.subjectglucose levelen
dc.titleDrug Delivery Systems for Diabetes Treatmenten
dc.typearticleen
dc.rights.licenseARR
dcterms.abstractНедељковић, Јован; Исеновић, Есма Р.; Зарић, Божидарка; Обрадовић, Милан М.; Судар-Миловановић, Емина; Лазић, Весна М.;
dc.rights.holder© 2019 Bentham Science Publishers
dc.citation.volume25
dc.citation.issue2
dc.citation.spage166
dc.citation.epage173
dc.identifier.wos000469202300007
dc.identifier.doi10.2174/1381612825666190306153838
dc.citation.rankM23
dc.identifier.pmid30848184
dc.type.versionpublishedVersion
dc.identifier.scopus2-s2.0-85068112555


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record